Pricing Log in Create free account

DiaMedica Therapeutics, Inc. (DMAC) vs Eupraxia Pharmaceuticals Inc. (EPRX)

DiaMedica Therapeutics, Inc. and Eupraxia Pharmaceuticals Inc. are both Biotechnology companies. DiaMedica Therapeutics, Inc. and Eupraxia Pharmaceuticals Inc. are of similar size ($446.2M and $433.6M). Across the 9 metrics below, DiaMedica Therapeutics, Inc. leads on 6 and Eupraxia Pharmaceuticals Inc. on 3.

Valuation

Metric DMAC EPRX Biotechnology median
P/E n/m n/m 8.50
P/S n/m n/m 9.71
P/B 10.68 4.38 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA n/m n/m 0.64
EV/Sales n/m n/m 9.21
Earnings yield (9.47%) (15.41%) (33.15%)
Free cash flow yield (7.70%) (8.72%) (25.50%)

Profitability

Metric DMAC EPRX Biotechnology median
Gross margin 0.00% — 65.16%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity (114.62%) (117.82%) (56.36%)
Return on assets (98.18%) (64.44%) (48.04%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric DMAC EPRX Biotechnology median
Revenue growth (TTM) — — 6.02%
EPS growth (last fiscal year) (16.67%) (35.53%) 30.26%
Revenue growth, 5-year CAGR — — 9.41%
Net income growth, 5-year CAGR 0.00% — 0.00%

Health

Metric DMAC EPRX Biotechnology median
Debt to equity 0.00 0.01 0.00
Current ratio 6.72 16.00 4.72
Net debt to EBITDA 1.70 2.11 0.96

Dividend

Metric DMAC EPRX Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric DMAC EPRX Biotechnology median
Market cap 433.56m 446.21m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack